I am particularly interested in applying my expertise within protein and cell line engineering to enable a faster drug development of advanced biologics. With the mission to integrate as many steps of the drug development chain to expediate time and cost to patient, my team consists of technology experts in both the discovery and bioproduction aspects, supported with strong indication specific clinical expertise per project.
I hold a PhD in molecular biotechnology and have special expertise in the areas of protein- and cell line engineering. My main research focus is about improving therapeutic bioproduction of challenging proteins and viral vectors in mammalian cells by cell line- and vector engineering. My projects mainly revolve around understanding and increasing the secretory capacity of the human HEK293 cell line.
My main focus area is transcriptomics analyzis of mammalian production systems. I am also developing tools to analyze deep-sequencing data from directed evolution experiments and Kozane, a web application for site-directed mutagenesis primer design.
My main area of interest is the secretory pathway of mammalian cells. In my research, I utilize transcriptomic data as a path to engineer cell lines for improvements on protein production and to get an insight into the cell responses that occur during productional pressure. Besides this, I also focus on the development of a mammalian cell surface display system for epitope mapping purposes.
My work focuses primarily on the development of Bispecific antibodies and a novel Bispecific format coined AffimAbs, as potential therapeutics within the field of immunotherapy and Autoimmune diseases. Additionally a great deal of the work focuses on the processability of Bispecifics in a platform based High throughput manner to adress inherent issues related to the production of these complex molecules.
My research focus mainly on mammalian cell line engineering, since these cell lines are widely used both in industrial and academics environments. One of the most commonly used mammalian cell lines, is CHO cells which are able to produce proteins with complex PTMs that are similar to those produced in humans. Despite this, CHO cells, display difficulties to express many target proteins with right post-translational modifications. Therefore the main focus of my projects is to address different bottlenecks for protein production and secretion in CHO cells. This in turn will enable the pharmaceutical companies to produce cheaper and more accessible medicine so that all patients can receive right treatment regardless of economical background.
I mainly work with mammalian cell lines with focus on optimizing and developing virus and protein production in HEK293-cells (various sub-categories) and CHO-S cells for various projects in cell and protein engineering. Alongside my main project I aid my colleagues in the research group with various analysis methods, with main expertise in Western Blot and RNA isolation.
My work mainly surrounds AAVs, where I engineer, produce and evaluate new AAV variants with the goal of improving the selectivity of the AAV.